EX-10.1 2 s102626_ex10-1.htm EHIBIT 10-1 CONFIDENTIAL TREATMENT REQUESTED. Confidential portions of this document have been redacted and have been separately filed with the Commission. Exhibit No. 10.1 Asset Transfer and License AgreementAsset Transfer and License Agreement • May 5th, 2020 • New York
Contract Type FiledMay 5th, 2020 JurisdictionThis Asset Transfer and License Agreement (the “Agreement”), is entered into as of February 17, 2015 (the “Effective Date”), by and between Revogenex Ireland Limited, an Irish limited company (“Revogenex”), and Coronado Biosciences, Inc., a Delaware corporation (“Coronado”). Coronado and Revogenex are both referred to herein as “Parties” or each individually, as a “Party.”
Asset Transfer and License AgreementAsset Transfer and License Agreement • March 13th, 2017 • Avenue Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 13th, 2017 Company Industry JurisdictionThis Asset Transfer and License Agreement (the “Agreement”), is entered into as of February 17, 2015 (the “Effective Date”), by and between Revogenex Ireland Limited, an Irish limited company (“Revogenex”), and Coronado Biosciences, Inc., a Delaware corporation (“Coronado”). Coronado and Revogenex are both referred to herein as “Parties” or each individually, as a “Party.”
Asset Transfer and License AgreementAsset Transfer and License Agreement • January 12th, 2017 • Avenue Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJanuary 12th, 2017 Company Industry JurisdictionThis Asset Transfer and License Agreement (the “Agreement”), is entered into as of February 17, 2015 (the “Effective Date”), by and between Revogenex Ireland Limited, an Irish limited company (“Revogenex”), and Coronado Biosciences, Inc., a Delaware corporation (“Coronado”). Coronado and Revogenex are both referred to herein as “Parties” or each individually, as a “Party.”
Asset Transfer and License AgreementAsset Transfer and License Agreement • February 18th, 2016 • Avenue Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 18th, 2016 Company Industry JurisdictionThis Asset Transfer and License Agreement (the “Agreement”), is entered into as of February 17, 2015 (the “Effective Date”), by and between Revogenex Ireland Limited, an Irish limited company (“Revogenex”), and Coronado Biosciences, Inc., a Delaware corporation (“Coronado”). Coronado and Revogenex are both referred to herein as “Parties” or each individually, as a “Party.”